RJA
PRVB

Raymond James & Associates’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Raymond James & Associates’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,626
Closed -$401K – 4034
2023
Q1 		$401K Sell
16,626
-5,456
-25% -$68.5K ﹤0.01% 3047
2022
Q4 		$233K Buy
22,082
+3,600
+19% +$29.1K ﹤0.01% 3362
2022
Q3 		$83K Buy
18,482
+5,652
+44% +$25.8K ﹤0.01% 3644
2022
Q2 		$51K Buy
12,830
+1,430
+13% +$6.78K ﹤0.01% 3784
2022
Q1 		$83K Sell
11,400
-8,600
-43% -$51.4K ﹤0.01% 3857
2021
Q4 		$112K Buy
20,000
+25
+0.1% +$159 ﹤0.01% 3844
2021
Q3 		$128K Buy
19,975
+2,550
+15% +$16.4K ﹤0.01% 3788
2021
Q2 		$147K Buy
17,425
+784
+5% +$6.33K ﹤0.01% 3759
2021
Q1 		$175K Buy
16,641
+1,320
+9% +$18.6K ﹤0.01% 3648
2020
Q4 		$260K Sell
15,321
-63
-0.4% -$944 ﹤0.01% 3215
2020
Q3 		$197K Buy
15,384
+5,320
+53% +$67.2K ﹤0.01% 3218
2020
Q2 		$142K Buy
+10,064
New +$127K ﹤0.01% 3220

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Raymond James & Associates's PRVB Position: Q2 2023 in Review

Raymond James & Associates sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 16,626 shares — an estimated $401K sold.

Raymond James & Associates first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $401K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Raymond James & Associates reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Raymond James & Associates sold 16,626 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $401K.
  • Raymond James & Associates first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • Raymond James & Associates's Provention Bio, Inc. Common Stock position peaked at $401K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.